Overexpression, purification, and crystal structure of native ER alpha LBD.

Several crystal structures of human estrogen receptor alpha ligand-binding domain (hERalpha LBD) complexed with agonist or antagonist molecules have previously been solved. The proteins had been modified in cysteine residues (carboxymethylation) or renatured in urea to circumvent aggregation and denaturation problems. In this work, high-level protein expression and purification together with crystallization screening procedure yielded high amounts of soluble protein without renaturation or modifications steps. The native protein crystallizes in the space group P3(2) 21 with three molecules in the asymmetric unit. The overall structure is very similar to that previously reported for the hERalpha LBD with cysteine carboxymethylated residues thus validating the modification approach. The present strategy can be adapted to other cases where the solubility and the proper folding is a difficulty.

[1]  M. Zeppezauer.  [24] Formation of large crystals , 1971 .

[2]  A. Venot,et al.  Statistical test of models and computerised parameter estimation for aldosterone binding in rat kidney , 1978 .

[3]  F. Studier,et al.  Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. , 1986, Journal of molecular biology.

[4]  E. Baulieu,et al.  Mineralocorticosteroid receptor of the chick intestine. Oligomeric structure and transformation. , 1989, The Journal of biological chemistry.

[5]  J. Schlom,et al.  The effects of induction conditions on production of a soluble anti-tumor sFv in Escherichia coli. , 1994, Protein engineering.

[6]  J. Navaza,et al.  AMoRe: an automated package for molecular replacement , 1994 .

[7]  L. Vuillard,et al.  Non-detergent sulphobetaines: a new class of mild solubilization agents for protein purification. , 1995, The Biochemical journal.

[8]  R. Evans,et al.  The RXR heterodimers and orphan receptors , 1995, Cell.

[9]  B. Katzenellenbogen,et al.  Nuclear hormone receptors: ligand-activated regulators of transcription and diverse cell responses. , 1996, Chemistry & biology.

[10]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[11]  M. Little,et al.  High level production of soluble single chain antibodies in small-scale Escherichia coli cultures. , 1997, Journal of immunological methods.

[12]  Zbigniew Dauter,et al.  Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.

[13]  John A. Katzenellenbogen,et al.  The estradiol pharmacophore: Ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site , 1997, Steroids.

[14]  P B Sigler,et al.  Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[15]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.

[16]  David A. Agard,et al.  The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen , 1998, Cell.

[17]  M Carlquist,et al.  Structure of the ligand‐binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist , 1999, The EMBO journal.

[18]  D. Moras,et al.  Estrogen receptor transcription and transactivation: Structure-function relationship in DNA- and ligand-binding domains of estrogen receptors , 2000, Breast Cancer Research.

[19]  D. Moras,et al.  Crystal Structure of a Mutant hERα Ligand-binding Domain Reveals Key Structural Features for the Mechanism of Partial Agonism* , 2001, The Journal of Biological Chemistry.